Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

7.540 +0.120 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,394,538
Open 7.480
Bid (Size) 7.570 (2)
Ask (Size) 7.700 (5)
Prev. Close 7.420
Today's Range 7.450 - 7.585
52wk Range 5.420 - 14.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Stocks to Bet On if You Want to Be Richer Than Elon Musk
If you can handle the heat of extreme speculation, you may want to throw some gambling funds at these stocks that can make you rich. 
Via InvestorPlace
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
From AbCellera Biologics Inc.
Via Business Wire

Performance

YTD
-20.55%
-20.55%
1 Month
-7.48%
-7.48%
3 Month
-25.57%
-25.57%
6 Month
-23.76%
-23.76%
1 Year
-22.67%
-22.67%

More News

Read More
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
From AbCellera Biologics Inc.
Via Business Wire
4 Analysts Have This to Say About AbCellera Biologics
Via Benzinga
Preview: AbCellera Biologics's Earnings
Via Benzinga
The Latest Analyst Ratings for AbCellera Biologics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript
Via The Motley Fool
AbCellera Reports Full Year 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Via InvestorPlace
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
From AbCellera Biologics Inc.
Via Business Wire
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
AbCellera and AbbVie Partner to Advance New Antibody Therapies
From AbCellera Biologics Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket
Via Benzinga
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Via Benzinga
Pinterest, Oracle And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
From Rallybio Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.